Rectal bioavailability of 6-mercaptopurine in children with acute lymphoblastic leukaemia: partial avoidance of "first-pass" metabolism. 1992

Y Kato, and T Matsushita, and H Uchida, and S Egi, and T Yokoyama, and K Mohri
Department of Pharmacy, Meiji College of Pharmacy, Tokyo, Japan.

Plasma levels and the area under the plasma concentration-time curve (AUC) values of 6-mercaptopurine (6-MP) were determined in a balanced crossover study of oral (powder) and rectal (macrogol suppository) administration to 5 children with acute lymphoblastic leukaemia (ALL). The AUC (538.6 ng.h.ml-1) after the rectal dose of 30 mg/m2 was approximately 1.5-times of that (365.5 ng.h.ml-1) after the oral dose of 87.5 mg/m2. The coefficients of variation of interindividual variability of the AUCs were 21.5% and 32.3%, respectively. The relative bioavailability of the macrogol suppository compared to the powder was approximately 4.39. These findings indicate that rectal administration of 6-MP could avoid the first-pass effect of this drug in the alimentary canal and/or liver, resulting in a large AUC of 6-MP, and so could reduce interindividual variability in plasma 6-MP concentrations. Rectal administration of 6-MP may be more effective than empirical oral dosing for the treatment of children with ALL, especially for patients with nausea and/or vomiting.

UI MeSH Term Description Entries
D008297 Male Males
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D000285 Administration, Rectal The insertion of drugs into the rectum, usually for confused or incompetent patients, like children, infants, and the very old or comatose. Anal Drug Administration,Drug Administration, Rectal,Instillation, Rectal,Rectal Drug Administration,Drug Administration, Anal,Rectal Administration,Administration, Anal Drug,Administration, Rectal Drug,Administrations, Anal Drug,Administrations, Rectal,Administrations, Rectal Drug,Anal Drug Administrations,Drug Administrations, Anal,Drug Administrations, Rectal,Instillations, Rectal,Rectal Administrations,Rectal Drug Administrations,Rectal Instillation,Rectal Instillations
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D001682 Biological Availability The extent to which the active ingredient of a drug dosage form becomes available at the site of drug action or in a biological medium believed to reflect accessibility to a site of action. Availability Equivalency,Bioavailability,Physiologic Availability,Availability, Biologic,Availability, Biological,Availability, Physiologic,Biologic Availability,Availabilities, Biologic,Availabilities, Biological,Availabilities, Physiologic,Availability Equivalencies,Bioavailabilities,Biologic Availabilities,Biological Availabilities,Equivalencies, Availability,Equivalency, Availability,Physiologic Availabilities
D015122 Mercaptopurine An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. 6-Mercaptopurine,1,7-Dihydro-6H-purine-6-thione,6-Mercaptopurine Monohydrate,6-Thiohypoxanthine,6-Thiopurine,6H-Purine-6-thione, 1,7-dihydro-,BW 57-323H,Leupurin,Mecaptopurine Anhydrous,Mercaptopurina Wellcome,Puri-Nethol,Purimethol,Purinethol,6 Mercaptopurine,6 Mercaptopurine Monohydrate,6 Thiohypoxanthine,6 Thiopurine,BW 57 323H,BW 57323H

Related Publications

Y Kato, and T Matsushita, and H Uchida, and S Egi, and T Yokoyama, and K Mohri
December 1979, Clinical pharmacology and therapeutics,
Y Kato, and T Matsushita, and H Uchida, and S Egi, and T Yokoyama, and K Mohri
August 2020, British journal of clinical pharmacology,
Y Kato, and T Matsushita, and H Uchida, and S Egi, and T Yokoyama, and K Mohri
October 1987, Lancet (London, England),
Y Kato, and T Matsushita, and H Uchida, and S Egi, and T Yokoyama, and K Mohri
July 1993, British journal of cancer,
Y Kato, and T Matsushita, and H Uchida, and S Egi, and T Yokoyama, and K Mohri
January 1984, Cancer chemotherapy and pharmacology,
Y Kato, and T Matsushita, and H Uchida, and S Egi, and T Yokoyama, and K Mohri
January 1986, Pediatric hematology and oncology,
Y Kato, and T Matsushita, and H Uchida, and S Egi, and T Yokoyama, and K Mohri
January 1991, European journal of clinical pharmacology,
Y Kato, and T Matsushita, and H Uchida, and S Egi, and T Yokoyama, and K Mohri
April 2017, The Lancet. Oncology,
Y Kato, and T Matsushita, and H Uchida, and S Egi, and T Yokoyama, and K Mohri
April 2010, Zhonghua er ke za zhi = Chinese journal of pediatrics,
Y Kato, and T Matsushita, and H Uchida, and S Egi, and T Yokoyama, and K Mohri
January 1997, European journal of clinical pharmacology,
Copied contents to your clipboard!